Deck the halls with resignations: LianBio CEO, CFO out; CRISPR Therapeutics CMO to leave in January
→ On Dec. 16, Yizhe Wang turned in his resignation as CEO of LianBio, while board member and Perceptive chief investment officer Adam Stone will grab the reins on an interim basis. The C-suite overhaul continued on Tuesday when finance chief Yi Larson also resigned, triggering another interim appointment as head of global finance Maggie Gu handles CFO responsibilities. Perceptive’s China play is facing an uncertain future despite its reasonably strong cash position. Kevin Tang’s shell company Concentra Biosciences made an unsolicited offer to buy LianBio that has since been rebuffed. LianBio has hinted at providing more details about its strategic review in Q1 after ending the licensing agreement with partner Bristol Myers Squibb for Camzyos in China and other Asian countries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.